633 related articles for article (PubMed ID: 21378538)
1. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
7. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
13. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
14. Impact of primary prophylaxis on febrile neutropenia within community practices in the US.
Hershman D; Hurley D; Wong M; Morrison VA; Malin JL
J Med Econ; 2009 Sep; 12(3):203-10. PubMed ID: 19723018
[TBL] [Abstract][Full Text] [Related]
15. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
16. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
Siena S; Piccart MJ; Holmes FA; Glaspy J; Hackett J; Renwick JJ
Oncol Rep; 2003; 10(3):715-24. PubMed ID: 12684649
[TBL] [Abstract][Full Text] [Related]
17. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
[TBL] [Abstract][Full Text] [Related]
19. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
